Northstrive Biosciences to present innovative obesity treatment EL-22 at UCLA symposium addressing muscle preservation in weight loss therapies.
Quiver AI Summary
PMGC Holdings Inc. announced that its subsidiary, Northstrive Biosciences Inc., will present its lead asset EL-22 at an upcoming UCLA symposium focused on anti-obesity treatments. The event aims to gather experts in obesity to discuss challenges in weight loss treatments, particularly the issue of muscle and bone loss associated with medications like GLP-1 receptor agonists. EL-22 is a first-in-class engineered probiotic designed to preserve muscle mass during weight loss, addressing a significant gap in current therapies which often result in the loss of lean muscle. Northstrive's presentation is scheduled for February 7th, 2025, and the company looks forward to engaging with key opinion leaders and investors in the field.
Potential Positives
- Northstrive Biosciences has been invited to present at a prestigious symposium hosted by UCLA, highlighting the company's recognition in the field of obesity treatment.
- The presentation of their lead asset, EL-22, addresses a significant gap in current obesity therapies by focusing on preserving muscle mass during weight-loss treatments.
- EL-22's innovative approach as a first-in-class engineered probiotic positions Northstrive Biosciences as a leader in addressing muscle wasting associated with GLP-1 receptor agonists, potentially enhancing market interest and partnerships.
Potential Negatives
- PMGC Holdings Inc. is relying on the unproven potential of their lead asset EL-22, which is still under development, indicating a lack of currently available solutions for the critical issue of muscle wastage from existing obesity treatments.
- The press release emphasizes the challenges surrounding obesity treatments and the associated risks of muscle and bone loss, suggesting that existing products might be inadequate, which could raise concerns among investors regarding market competitiveness.
- Forward-looking statements in the release highlight inherent uncertainties and risks that could impact the company's future performance, potentially undermining investor confidence.
FAQ
What is the purpose of the symposium organized by UCLA Metabolism Theme?
The symposium aims to address challenges and emerging solutions related to anti-obesity treatments.
What is EL-22, presented by Northstrive Biosciences?
EL-22 is a first-in-class engineered probiotic designed to preserve muscle mass during weight loss treatments.
When will Northstrive Biosciences present at the symposium?
Northstrive Biosciences is scheduled to present on Friday, February 7th at 11:30 am PT.
What challenges does EL-22 address in weight loss treatments?
EL-22 addresses muscle and bone loss associated with current GLP-1 receptor agonist therapies.
How can I learn more about PMGC Holdings Inc.?
You can visit PMGC Holdings Inc.'s website at https://www.pmgcholdings.com for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ELAB Hedge Fund Activity
We have seen 7 institutional investors add shares of $ELAB stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SABBY MANAGEMENT, LLC added 2,541,779 shares (+inf%) to their portfolio in Q3 2024, for an estimated $210,967
- WHITTIER TRUST CO OF NEVADA INC removed 80,666 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $6,695
- GEODE CAPITAL MANAGEMENT, LLC added 45,130 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,745
- TWO SIGMA SECURITIES, LLC added 43,265 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,590
- TOWER RESEARCH CAPITAL LLC (TRC) added 39,128 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,247
- HRT FINANCIAL LP added 35,853 shares (+inf%) to their portfolio in Q3 2024, for an estimated $2,975
- DIVERSIFY ADVISORY SERVICES, LLC removed 25,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $57,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that Northstrive Biosciences Inc. (“Northstrive Biosciences”) has been invited to present at the upcoming symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions organized by UCLA Metabolism Theme. UCLA Metabolism Theme is an initiative at UCLA David Geffen School of Medicine aiming to facilitate campus wide interdisciplinary research in the field of metabolism involving basic, clinical, and industry collaborations
This timely symposium brings together industry leading, obesity focused clinicians, researchers, drug developers and investors to address the challenges brought up by weight loss treatments. Northstrive Biosciences has been invited to present lead asset EL-22, which leverages a first-in-class engineered probiotic approach for preserving muscle while on weight loss treatments.
“The rise of anti-obesity medications has put the spotlight on the challenges being faced, particularly the management of muscle and bone loss associated with GLP-1 receptor agonists,” stated Orian Shirihai, MD, PhD, the Director of UCLA’s Metabolism Theme. “We organized this event to gather obesity’s leading opinion leaders to review the gaps and highlight the emerging solutions. I am pleased that Northstrive Biosciences has accepted our invitation to give a talk at the event.”
Northstrive Biosciences will showcase EL-22 , a first-in-class engineered probiotic designed to preserve muscle mass in patients undergoing weight-loss treatments, including GLP-1 receptor agonists. This groundbreaking therapeutic addresses a critical gap in current obesity treatments, where up to 50% of body weight lost is lean muscle mass—a side effect that has yet to be adequately addressed by approved therapies.
[1][ 2 ] Studies show that approximately 30-50% of body weight lost with GLP-1 based therapy is lean muscle mass, a common side effect that has no currently approved treatment. Northstrive’s lead asset EL-22 is being developed as a potential combination therapy with GLP-1 receptor agonists for preserving muscle while on weight loss treatments.
“We are looking forward to presenting EL-22 as a next-generation solution to the common muscle wasting side effect,” said Deniel Mero, Co-founder of Northstrive Biosciences. “We’re honored to contribute a lecture and are looking to connect with key opinion leaders, investors and established pharma companies in the obesity space.”
Northstrive Biosciences’ management is scheduled to present on Friday, February 7 th at 11:30 am PT.
About Northstrive Biosciences
Northstrive Biosciences Inc., a PMGC Holdings company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov . All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
[email protected]
1 Reference: Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019 Sep;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247
2 Reference: Beavers KM, Cortes TM, Foy CM, et al. GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity (Silver Spring) . 2024; 1-13. https://doi.org/10.1002/oby.24172